Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions

Abstract

Effective revascularization of peripheral artery disease relies on periprocedural pharmacological regulation of the clotting cascade. Patient-specific factors such as cardiovascular risk factors, contraindications, and individual psychosocial factors must be considered when initiating post revascularization management. Management with anticoagulant and antiplatelet agents is discussed to guide the interventionalist on which therapy may be appropriate for their patient. While exact treatment may be institution and provider dependent, the interventionist must be familiar with the available classes of medications and how they can be prescribed in the postprocedural setting to improve cardiovascular outcomes.

Keywords

anticoagulant - antiplatelet - peripheral artery disease - dual-antiplatelet therapy - interventional radiology

Publication History

Article published online:
17 November 2022

• References

• 1 Lopez AD, Murray CCJL. The global burden of disease, 1990-2020. Nat Med 1998; 4 (11) 1241-1243
• 2 Guez D, Hansberry DR, Gonsalves CF. et al. Recent trends in endovascular and surgical treatment of peripheral arterial disease in the Medicare population. AJR Am J Roentgenol 2020; 214 (05) 962-966
• 3 Davidson JC, Rahim S, Hanks SE. et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part I: Review of anticoagulation agents and clinical considerations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol 2019; 30 (08) 1155-1167
• 4 Wiersema AM, Watts C, Durran AC. et al. The use of heparin during endovascular peripheral arterial interventions: a synopsis. Scientifica (Cairo) 2016; 2016: 1456298
• 5 Paez Espinosa EV, Murad JP, Khasawneh FT. Aspirin: pharmacology and clinical applications. Thrombosis 2012; 2012: 173124
• 6 Kalra K, Franzese CJ, Gesheff MG. et al. Pharmacology of antiplatelet agents. Curr Atheroscler Rep 2013; 15 (12) 371
• 7 Hess CN, Norgren L, Ansel GM. et al. A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. Circulation 2017; 135 (25) 2534-2555
• 8 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery | Circulation. Accessed February 13, 2022 at: https://www.ahajournals.org/doi/10.1161/cir.0000000000000404
• 9 Singh N, Ding L, Magee GA, Shavelle DM, Kashyap VS, Garg PK. Discharge prescription patterns for antiplatelet therapy following lower extremity peripheral vascular intervention. Circ Cardiovasc Interv 2020; 13 (08) e008791
• 10 Mehta RP, Johnson MS. Update on anticoagulant medications for the interventional radiologist. J Vasc Interv Radiol 2006; 17 (04) 597-612
• 11 Hirsh J. Antithrombotic therapy in deep vein thrombosis and pulmonary embolism. Am Heart J 1992; 123 (4, Pt 2): 1115-1122
• 12 Patel S, Singh R, Preuss CV, Patel N. Warfarin. In: StatPearls. StatPearls Publishing; 2022. Accessed February 19, 2022 at: http://www.ncbi.nlm.nih.gov/books/NBK470313/
• 13 Diagnosis and Treatment of Lower Extremity Venous Thromboembolism. A Review | Pulmonary Medicine | JAMA | JAMA Network. Accessed February 19, 2022 at: https://jamanetwork-com.libproxy.lib.unc.edu/journals/jama/fullarticle/2772499
• 14 Gottsäter A. Antithrombotic treatment in lower extremity peripheral arterial disease. Front Cardiovasc Med 2021; 8: 773214
• 15 WAVE Investigators. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am Heart J 2006; 151 (01) 1-9
• 16 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382 (21) 1994-2004
• 17 Talukdar A, Wang SK, Czosnowski L. et al. Safety and efficacy of rivaroxaban compared with warfarin in patients undergoing peripheral arterial procedures. J Vasc Surg 2017; 66 (04) 1143-1148
• 18 Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006; 62 (05) 509-511
• 19 Patel IJ, Rahim S, Davidson JC. et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol 2019; 30 (08) 1168-1184 .e1
• 20 Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med 2011; 12 (04) 386-392
• 21 Jaffe TA, Raiff D, Ho LM, Kim CY. Management of anticoagulant and antiplatelet medications in adults undergoing percutaneous interventions. AJR Am J Roentgenol 2015; 205 (02) 421-428
• 22 Duschek N, Vafaie M, Skrinjar E. et al. Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial. J Thromb Haemost 2011; 9 (11) 2159-2167
• 23 Jupalli A, Iqbal AM. Enoxaparin. In: StatPearls. StatPearls Publishing; 2022. Accessed February 19, 2022 at: http://www.ncbi.nlm.nih.gov/books/NBK539865/
• 24 Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3, Suppl): 188S-203S
• 25 Brodmann M, Dorr A, Hafner F. et al. Safety and efficacy of periprocedural anticoagulation with enoxaparin in patients undergoing peripheral endovascular revascularization. Clin Appl Thromb Hemost 2014; 20 (05) 530-535
• 26 Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet 2020; 396 (10264): 1767-1776
• 27 Baron SJ, Yeh RW, Cruz-Gonzalez I. et al. Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease. Catheter Cardiovasc Interv 2008; 72 (01) 116-120
• 28 Olmedo W, Villablanca PA, Sanina C. et al. Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: a systematic review and meta-analysis. Vascular 2019; 27 (01) 78-89
• 29 Ambler GK, Waldron CA, Contractor UB, Hinchliffe RJ, Twine CP. Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease. Br J Surg 2020; 107 (01) 20-32
• 30 Singh D, Gupta K, Vacek JL. Anticoagulation and antiplatelet therapy in acute coronary syndromes. Cleve Clin J Med 2014; 81 (02) 103-114
• 31 Cho S, Lee YJ, Ko YG. et al. Optimal strategy for antiplatelet therapy after endovascular revascularization for lower extremity peripheral artery disease. JACC Cardiovasc Interv 2019; 12 (23) 2359-2370
• 32 Mahnken AH, Boullosa Seoane E, Cannavale A. et al. CIRSE Clinical Practice Manual. Cardiovasc Intervent Radiol 2021; 44 (09) 1323-1353
• 33 Conte MS, Pomposelli FB, Clair DG. et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg 2015; 61 (03) 2S-41S.e1
• 34 Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA 2019; 321 (03) 277-287
• 35 Baigent C, Blackwell L, Collins R. et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849-1860
• 36 Bhatt DL, Fox KAA, Hacke W. et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354 (16) 1706-1717
• 37 Hiatt WR, Fowkes FGR, Heizer G. et al; EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376 (01) 32-40
• 38 Goli RR, Contractor MM, Nathan A, Tuteja S, Kobayashi T, Giri J. Antiplatelet therapy for secondary prevention of vascular disease complications. Curr Atheroscler Rep 2017; 19 (12) 56
• 39 O'Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey. Ann Intern Med 2019; 171 (08) 596-598
• 40 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231 (25) 232-235
• 41 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975; 72 (08) 3073-3076
• 42 Hussain MA, Al-Omran M, Creager MA, Anand SS, Verma S, Bhatt DL. Antithrombotic therapy for peripheral artery disease: recent advances. J Am Coll Cardiol 2018; 71 (21) 2450-2467
• 43 Gerhard-Herman MD, Gornik HL, Barrett C. et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135 (12) e686-e725
• 44 Collaborative overview of randomised trials of antiplatelet therapy–III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308 (6923): 235-246
• 45 Bowman L, Mafham M, Stevens W. et al; ASCEND Study Collaborative Group. ASCEND: a study of cardiovascular events in diabetes: characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. Am Heart J 2018; 198: 135-144
• 46 McNeil JJ, Nelson MR, Woods RL. et al; ASPREE Investigator Group. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018; 379 (16) 1519-1528
• 47 Gaziano JM, Brotons C, Coppolecchia R. et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392 (10152): 1036-1046
• 48 Arnett DK, Blumenthal RS, Albert MA. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140 (11) e596-e646
• 49 Anand SS, Caron F, Eikelboom JW. et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS Trial. J Am Coll Cardiol 2018; 71 (20) 2306-2315
• 50 Bauersachs RM, Szarek M, Brodmann M. et al; VOYAGER PAD Committees and Investigators. Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial. J Am Coll Cardiol 2021; 78 (04) 317-326
• 51 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038): 1329-1339
• 52 Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2000; (02) CD001246
• 53 Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 2012; 125 (10) 1276-1287 , discussion 1287
• 54 von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 2005; 112 (19) 2946-2950
• 55 Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3 (01) 85-92
• 56 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49 (14) 1505-1516
• 57 Wallentin L, Varenhorst C, James S. et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29 (01) 21-30
• 58 Wiviott SD, Braunwald E, McCabe CH. et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
• 59 Wallentin L, Becker RC, Budaj A. et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
• 60 Gurbel PA, Bliden KP, Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120 (25) 2577-2585
• 61 Manolis AA, Manolis TA, Melita H, Mikhailidis DP, Manolis AS. Update on cilostazol: a critical review of its antithrombotic and cardiovascular actions and its clinical applications. J Clin Pharmacol 2022; 62 (03) 320-358
• 62 Megaly M, Abraham B, Saad M. et al. Outcomes with cilostazol after endovascular therapy of peripheral artery disease. Vasc Med 2019; 24 (04) 313-323
• 63 Zen K, Takahara M, Iida O. et al; ZEPHYR Investigators. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. J Vasc Surg 2017; 65 (03) 720-725
• 64 Stangl PA, Lewis S. Review of currently available GP IIb/IIIa inhibitors and their role in peripheral vascular interventions. Semin Intervent Radiol 2010; 27 (04) 412-421
• 65 Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs 2013; 73 (15) 1681-1709
• 66 Tepe G, Hopfenzitz C, Dietz K. et al. Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis–APART trial. Radiology 2006; 239 (03) 892-900
• 67 Duda SH, Tepe G, Luz O. et al. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone–a randomized pilot trial (the PROMPT Study). Platelet receptor antibodies in order to manage peripheral artery thrombosis. Radiology 2001; 221 (03) 689-696
• 68 Arora S, Panaich SS, Patel N. et al. Impact of glycoprotein IIb/IIIa inhibitors use on outcomes after lower extremity endovascular interventions from nationwide inpatient sample (2006-2011). Catheter Cardiovasc Interv 2016; 88 (04) 605-616
• 69 Bonaca MP, Morrow DA. SCH 530348: a novel oral thrombin receptor antagonist. Future Cardiol 2009; 5 (05) 435-442
• 70 Morrow DA, Braunwald E, Bonaca MP. et al; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15) 1404-1413
• 71 Qamar A, Morrow DA, Creager MA. et al. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: analysis from the TRA 2°P-TIMI 50 trial. Vasc Med 2020; 25 (02) 124-132
• 72 Peeters Weem SMO, van Haelst STW, den Ruijter HM, Moll FL, de Borst GJ. Lack of evidence for dual antiplatelet therapy after endovascular arterial procedures: a meta-analysis. Eur J Vasc Endovasc Surg 2016; 52 (02) 253-262
• 73 Navarese EP, Wernly B, Lichtenauer M. et al. Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - a meta-analysis. Int J Cardiol 2018; 269: 292-297
• 74 Gresele P, Migliacci R. The peripheral arterial disease subgroup in the CHARISMA trial: does it tell us anything new?. Eur Heart J 2009; 30 (02) 131-132
• 75 Belch JJF, Dormandy J, Biasi GM. et al; CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52 (04) 825-833 , 833.e1–833.e2
• 76 Tepe G, Bantleon R, Brechtel K. et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy–the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol 2012; 22 (09) 1998-2006
• 77 Bonaca MP, Bhatt DL, Storey RF. et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67 (23) 2719-2728
• 78 Eikelboom JW, Connolly SJ, Bosch J. et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
• 79 Kaplovitch E, Eikelboom JW, Dyal L. et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol 2021; 6 (01) 21-29
• 80 Hiatt WR, Bonaca MP, Patel MR. et al. Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety. Circulation 2020; 142 (23) 2219-2230
• 81 Moll F, Baumgartner I, Jaff M. et al; ePAD Investigators. Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial. J Endovasc Ther 2018; 25 (02) 158-168
• 82 Asiimwe IG, Zhang EJ, Osanlou R, Jorgensen AL, Pirmohamed M. Warfarin dosing algorithms: a systematic review. Br J Clin Pharmacol 2021; 87 (04) 1717-1729
• 83 Morris TA. Heparin and low molecular weight heparin: background and pharmacology. Clin Chest Med 2003; 24 (01) 39-47
• 84 Patti G, Micieli G, Cimminiello C, Bolognese L. The role of clopidogrel in 2020: a reappraisal. Cardiovasc Ther 2020; 2020: 8703627
• 85 Capodanno D, Milluzzo RP, Angiolillo DJ. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. Ther Adv Cardiovasc Dis 2019; 13: 1753944719893274
• 86 Arif SA, D'Souza J, Gil M, Gim S. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. Am J Health Syst Pharm 2015; 72 (19) 1615-1622